In this phase 3 , open-label study , we randomly assigned 647 previously untreated patients with HCV genotype 1 infection without cirrhosis to receive ledipasvir and sofosbuvir ( ledipasvir-sofosbuvir ) for 8 weeks , ledipasvir-sofosbuvir plus ribavirin for 8 weeks , or ledipasvir-sofosbuvir for 12 weeks .